

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse Osteoactivin/GPNMB in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody does not cross-react with recombinant human Osteoactivin.
Source	Monoclonal Rat IgG _{2B} Clone # 297310
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse Osteoactivin/GPNMB Lys23-Asn502 Accession # NP_444340
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Osteoactivin (also named GPNMB and DC-HIL) is a 125 kDa, intracellular glycoprotein that is associated with cell endosomal/lysosomal compartments (1, 2). Mouse osteoactivin is synthesized as a type I, transmembrane, 574 amino acid (aa) precursor that contains a 22 aa signal sequence, a 478 aa luminal/extracellular domain, a 23 aa transmembrane segment and a 51 aa cytoplasmic tail. The luminal region contains an N-terminal heparin-binding motif, multiple glycosylation sites, an RGD motif and a 130 aa PKD domain. The intracellular tail also has an RGD motif, plus an ITAM (Y-x-x-I) and lysosomal targeting (L-L) motif. The extracellular/luminal region is 89% and 74% aa identical to the equivalent regions in rat and human, respectively. Cells known to express osteoactivin include osteoblasts, dendritic cells, and melanocytes, plus fetal chondrocytes and stratum basale keratinocytes (2, 3). Osteoactivin is reported to bind to heparan sulfate-proteoglycan, possibly on the surface of fibroblasts and endothelial cells (2). It may also interact with integrins.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc., and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.